Covidien (COV) Beats EPS Estimates by a Penny

NEW YORK (TheStreet) -- Covidien (COV) stock is slipping on Friday, despite better-than-expected second-quarter results on its bottom line. 

Over the three months to March, the medical supplies distributor earned 96 cents a share, excluding one-time charges, a penny higher than analysts surveyed by Thomson Reuters forecast. 

SELL NOW: If you own any of the 900 stocks that TheStreet Quant Ratings has identified as a 'Sell'...you could potentially lose EVERYTHING in the next 6-12 months. Learn more.

Unadjusted net income of 97 cents a share was 5 cents higher than a year earlier and beat estimates by 2 cents. 

Revenue climbed 2.4% year over year to $2.59 billion. Analysts had expected $2.61 billion. 

Management reiterated full-year guidance of 2% to 5% revenue growth, assuming a range of $10.44 billion to $10.75 billion. Analysts expect 4.1% growth or total revenue of $10.65 billion. 

By late afternoon, shares were down 2.6% to $69.10.

Must read: Warren Buffett's 10 Favorite Growth Stocks

STOCKS TO BUY: TheStreet's Stocks Under $10 has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

More from Markets

5 Stocks That Are Screaming Buys Right Now

5 Stocks That Are Screaming Buys Right Now

General Electric Booted From Dow, Replaced by Walgreens

General Electric Booted From Dow, Replaced by Walgreens

European Union Says Tariffs on U.S. Imports Will Kick In on June 22

European Union Says Tariffs on U.S. Imports Will Kick In on June 22

Stocks Rise, GE Dropped From the Dow, Starbucks, Oracle - 5 Things You Must Know

Stocks Rise, GE Dropped From the Dow, Starbucks, Oracle - 5 Things You Must Know

Global Stocks Rebound But US-China Trade War Concerns Keep Investors on Edge

Global Stocks Rebound But US-China Trade War Concerns Keep Investors on Edge